All News

change,future,lens,clarity

‘Strong’ treatment predictions in inflammatory myositis

Janet Pope, MD, MPH, FRCPC

Presented at EULAR 2026 London, Brepocitinib dual TYK2/JAK1 inhibitor with successful Phase 3 VALOR trial demonstrating significant improvement in skin and muscle symptoms in dermatomyositis (DM).

Read Article
EULAR flags

Vasculitis Updates: Glucocorticoid use in AAV and GCA

2026 EULAR Press Release

Glucocorticoids are the cornerstone of initial vasculitis treatment, used to rapidly control inflammation and protect vital organs. EULAR has recommendations that cover glucocorticoid use in ANCA associated vasculitides (AAV) and large vessel vasculitis, including giant cell arteritis (GCA).1,2 But the evidence base continues to grow about their use – especially over the long term.

Read Article
EULAR flags

Digital Platforms and AI

2026 EULAR Press Release

EULAR works with the network of national organisations of People with Arthritis/Rheumatism in Europe (PARE) to ensure the voices of people with RMD are heard and have influence – creating powerful alliances that make a real difference. Artificial intelligence is another potential ally in that fight. At the EULAR 2026 Congress in London, work was presented from three PARE initiatives that showcase how digital tools can be used in treatment education and decision-making, and potentially avoid the use of general web searches to answer important questions.

Read Article
RheumNow’s expanded coverage of the #EULAR2026 annual meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.

Dr. John Cush RheumNow ( View Tweet)

Proud to present POS0784 at #EULAR2026. RheumACaN education + pathway redesign across primary and secondary care improved early inflammatory arthritis referrals within 3 working days from 52% to 70%, exceeding the national benchmark. 95% of clinicians changed their practice. https://t.co/W6VViVRndp

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
DAY 1 & 2 Recap: EULAR 2026 Highlights https://t.co/uVMerChWN6

Links:

Dr. John Cush RheumNow ( View Tweet)

@RheumNow HOT #Obesity session (7) 📢A call for action Current RMD treatments ignore obesity: They all target immune response but miss the metabolic-inflammatory loop Breaking that cycle may be the missing piece Obesity must be part of every rheumatology plan #EULAR2026 @rheumnow

Nelly ZIADE 🍀 Nellziade ( View Tweet)

DR JOHN STONE gives Overview Of #IgG4 New non B cell depleter #obexelimab N=194 in RCT To add to B cell depletion w #Inebilizumab Off label but used also #Rituximab #steroids #Immunesuppressives Other investigational drugs Ex #JAKi #EULAR2026 @RheumNow #OP018 #RULARbest https://t.co/Y4saGYcdww

Links:

Janet Pope Janetbirdope ( View Tweet)
🔍 Are 2025 ASAS-SPARTAN criteria valid in early axSpA? SPACE cohort (n=669): HIGH specificity (97.5%) but LOWER sensitivity (60%) vs 2009 criteria (83%) #OP0239 #EULAR2026 @RheumNow https://t.co/9wNbtcbP0l

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
A Field Whose Time Has Come: Launching the EULAR Study Group on Geriatric Rheumatology EULAR launches a Study Group on Geriatric Rheumatology — clinics increasingly serve older patients with multimorbidity, polypharmacy, frailty, cognitive and functional limits, yet research

Dr. John Cush RheumNow ( View Tweet)

Transitioning from pediatrics to adult rheumatology for patients with autoinflammatory disease such as #AOSD should be done with administrative support and the right hand off. @RheumNow #EULAR2026 plenary talk https://t.co/N8qB7jrZfM

Links:

Bella Mehta bella_mehta ( View Tweet)
Defining the TRM- SLE patient response. Patient eligibility would be the key #EULAR2026 @RheumNow https://t.co/5CzQYgc12K

Links:

Bella Mehta bella_mehta ( View Tweet)
Treatment for #lupus #brain #fog?! #small #RCT of Memantine a N-methyl-D-aspartate receptor (NDAR) antagonist used in #Alzheimers SLE-more permeability in #brain #SLE -antiDNA cross reacting w NDAR #memantine N=19 v #PBO N=25 showed more improvemt #EULAR2026 @RheumNow POS701 https://t.co/qvHOy9oDS7

Links:

Janet Pope Janetbirdope ( View Tweet)
RD in #IBD: 18.6% of 650 IBD pts affected, most commonly peripheral arthritis and AxSpa. Key finding: 14% of rheumatic manifestations preceded IBD diagnosis. Rheumatologists may see these pts first. GI-rheum collaboration is essential. @RheumNow #EULAR2026 POS0807 https://t.co/028yzOxJ2R

Links:

Jiha Lee JihaRheum ( View Tweet)
What defines MRI indicative of axSpA? This systematic lit review show adapting more stringent cutoffs in BME (>=4 SIJ quads, erosion >=3 quads, fat >=5 SIJ quads) & combined BME + structural lesions inc specificity. Time for updated definitions? AbsPOS0866 @RheumNow #EULAR2026 https://t.co/gkVbcOAiD3

Links:

sheila RHEUMarampa ( View Tweet)
Weight management should be discussed!! Obesity management will help rheumatic diseases. EULAR guidelines below. No ACR ones exist. Best evidence in OA and Gout. #EULAR2026 plenary @RheumNow https://t.co/hBu4YeXZbu

Links:

Bella Mehta bella_mehta ( View Tweet)
Metaflammation !! A new term I learnt at #EULAR2026 plenary. @RheumNow Inflammation triggered by metabolic abnormalities. This may be the reason a lot of our inflammatory arthritis patients on GLP1 drugs(other indications) have thier disease activities improving. Emerging data.

Bella Mehta bella_mehta ( View Tweet)

#OP0239: validating 2025 ASAS-SPARTAN axSpA classification criteria in the SPACE cohort. Revised criteria showed high specificity but lower sensitivity than 2009 criteria, reflecting greater emphasis on imaging & less reliance on clinical features alone. #EULAR2026 @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB. All content is independently chosen and produced by the RheumNow faculty.

Dr. John Cush RheumNow ( View Tweet)

Why are GLP1 agonists important in rheumatology- plenary at #EULAR2026 Presence on leucocytes- change from pro inflammatory to anti inflammatory casade Also in fibroblasts in rheumatoid arthritis. Trials on the way for OA, Gout, as well as IBD. @RheumNow https://t.co/WJ6actAzrv

Links:

Bella Mehta bella_mehta ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×